Artificial Intelligence

After a multi-year slump, investors poured nearly $14 billion into cybersecurity in 2025, driven by AI risks and the relentless growth of cybercrime.

The San Diego-based credit union is partnering with the AI lending giant to expand loan access, signaling a major shift in how local finance competes.

Celebrating 60 years, Sensormatic Solutions unveils new AI and RFID tools to fight shrink, boost inventory accuracy, and transform the shopper experience.

Lifepoint Health partners with iScribeHealth, deploying ambient AI scribes across its network to reduce documentation and improve patient care.

Triad Partners' 'Launch 2026' event features Alex Rodriguez and an AI mastermind to help financial advisors redefine success and build lasting legacies.

Cynomi hires ThreatLocker's former CRO Shane Deegan, signaling a major push to help MSPs turn cybersecurity from a cost center into a profit engine.

A biotech firm's promising concussion therapy, backed by NFL's Alex Smith, shows an 85% responder rate and now seeks public funding for its final push.

At CES 2026, an ice cream-scooping robot reveals PaXini's full-stack plan to solve embodied AI's biggest challenges with advanced tactile sensors and data.

The deal merges digital orchestration with field AI, promising pharma a unified, rapid-deployment engagement solution to challenge industry giants.

A Boston biotech, armed with $62M and a new name, unveils a plan to build a universal model of the cell, aiming to predict and control its behavior.

Wearable Devices and Rokid partner to bring touchless gesture control to smart glasses, promising a future where a flick of a finger runs your world.

A new AI receptionist integrated into HawkSoft aims to end missed calls and manual data entry. But are independent agencies ready to trust the technology?

Pharma giant Lilly and AI biotech BigHat are teaming up to solve a critical flaw in AI drug discovery, aiming to unlock a new generation of therapies.

The deal creates an end-to-end commercialization powerhouse, tackling pharma's toughest payer, reimbursement, and patient affordability challenges.

Navan CEO Ariel Cohen will pitch his growth strategy at the Needham conference, a key test for the travel tech firm amid stock declines and high hopes.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

Formerly Pure Harvest, Mixie Technologies acquires a stake in digital twin firm HoloTwin, signaling a major strategic shift into AI and platform solutions.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

A new patient app from BrightInsight and Sanofi reduced therapy discontinuation by 4%, proving digital tools can solve medicine's adherence problem.